We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
+32.82%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.14B
AUM Growth
+$551M
(+94%)
Cap. Flow
+$421M
Cap. Flow
% of AUM
37.05%
Top 10 Holdings %
Top 10 Hldgs %
39.86%
Holding
141
New
51
Increased
36
Reduced
11
Closed
41
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VRAY
ViewRay, Inc.
VRAY
|
+$18.2M |
| 2 |
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
|
+$10.6M |
| 3 |
IMDX
Insight Molecular Diagnostics
IMDX
|
+$10.3M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$5.48M |
| 5 |
SRACU
Stable Road Acquisition Corp. Unit
SRACU
|
+$4.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$11.1M |
| 2 |
Gilead Sciences
GILD
|
+$9.51M |
| 3 |
Smith & Nephew
SNN
|
+$8.66M |
| 4 |
Baxter International
BAX
|
+$4.96M |
| 5 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$3.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 26.48% |
| 2 | Industrials | 0.92% |
| 3 | Consumer Staples | 0.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Rocket Pharmaceuticals
RCKT
$382M
| $2.48M | 0.22% |
+109,000
| New | +$1.82M |
|
77
Evolus
EOLS
$551M
| $2.38M | 0.21% |
+195,583
| New | +$2.76M |
|
78
Cabaletta Bio
CABA
$455M
| $2.16M | 0.19% |
+154,792
| New | +$1.83M |
|
|
RCM
79
CALL
DELISTED
R1 RCM Inc. Common Stock
RCM
| $2.12M | 0.19% |
163,000
-187,000
| -53% | -$2.14M |
|
|
INOV
80
CALL
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| $2.05M | 0.18% |
109,000
-191,000
| -64% | -$3.2M |
|
81
Ardelyx
ARDX
$982M
| $2.05M | 0.18% |
272,605
+132,520
| +95% | +$805K |
|
82
KALA BIO
KALA
$16.3M
| $1.97M | 0.17% |
214
+81
| +61% | +$782K |
|
83
CALL
Natera
NTRA
$45.1B
| $1.82M | 0.16% |
+54,000
| New | +$1.99M |
|
84
Greenlane Holdings
GNLN
$1.24M
| – | – |
0
| – | – |
|
|
DERM
85
DELISTED
Dermira, Inc.
DERM
| $1.67M | 0.15% |
+110,350
| New | +$953K |
|
86
Adaptive Biotechnologies
ADPT
$4.04B
| $1.62M | 0.14% |
+54,010
| New | +$1.55M |
|
87
Neurogene
NGNE
$714M
| $1.58M | 0.14% |
+6,409
| New | +$638K |
|
88
CALL
Novavax
NVAX
$1.31B
| $1.3M | 0.11% |
327,800
| – | – |
|
89
Stereotaxis
STXS
$145M
| $1.29M | 0.11% |
+244,103
| New | +$970K |
|
90
Savara
SVRA
$1.14B
| $1.29M | 0.11% |
+287,110
| New | +$346K |
|
91
uniQure
QURE
$3.12B
| $1.17M | 0.1% |
16,350
+1,350
| +9% | +$74.1K |
|
92
Alkermes
ALKS
$8.26B
| $1.1M | 0.1% |
+54,000
| New | +$1.07M |
|
|
AVDL
93
DELISTED
Avadel Pharmaceuticals
AVDL
| $823K | 0.07% |
109,000
-12,435
| -10% | -$65.7K |
|
94
Abeona Therapeutics
ABEO
$422M
| $802K | 0.07% |
+9,810
| New | +$692K |
|
|
SPPI
95
CALL
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $794K | 0.07% |
+218,000
| New | +$1.76M |
|
|
AMRN
96
Amarin Corp
AMRN
$296M
| $740K | 0.07% |
+1,725
| New | +$655K |
|
|
CBAY
97
CALL
DELISTED
Cymabay Therapeutics
CBAY
| $641K | 0.06% |
327,000
+27,000
| +9% | +$101K |
|
|
APLT
98
DELISTED
Applied Therapeutics
APLT
| $595K | 0.05% |
+21,810
| New | +$374K |
|
|
HEXO
99
PUT
DELISTED
HEXO Corp. Common Shares
HEXO
| $239K | 0.02% |
+2,679
| New | +$353K |
|
|
MAPSW
100
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
| $20K | ﹤0.01% |
+50,000
| New | +$29.1K |
|
Similar funds
BCA
RC
DOFI
SCI
LPC
GBCP
SCTC
M
Pura Vida Investments's Q4 2019 Portfolio in Review
As of Q4 2019, Pura Vida Investments held 141 positions worth $1.14B, up 94% from $585M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Pura Vida Investments deployed $421M of net new capital in Q4 2019, opening 51 new positions and adding to 36 existing holdings. Its largest new stake was Insight Molecular Diagnostics: 284,829 shares worth $12.8M.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 40% a quarter earlier, followed by Industrials and Consumer Staples.
On the sell side, the largest reduction was Establishment Labs, an estimated $1.39M trimmed.
- Pura Vida Investments's largest Q4 2019 buy was Insight Molecular Diagnostics: 284,829 shares worth $12.8M.
- Pura Vida Investments added most to ViewRay, Inc. in Q4 2019, an estimated $18.2M increase.
- Pura Vida Investments's biggest Q4 2019 reduction was Establishment Labs, cutting an estimated $1.39M.
- Pura Vida Investments fully exited Regeneron Pharmaceuticals in Q4 2019, selling an estimated $11.1M.
- Pura Vida Investments's ten largest holdings make up 40% of its $1.14B portfolio in Q4 2019.
- Pura Vida Investments opened 51 new positions and closed 41 in Q4 2019.
- Pura Vida Investments's portfolio value rose 94% quarter-over-quarter to $1.14B.
Based on Pura Vida Investments's 13F filing for Q4 2019, filed 14 Feb 2020.